Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290934 · ClinicalTrials.gov registry record · Phase 2
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT06290934: Active Phase 2 study of Ulcerative Colitis, sponsored by Gilead Sciences.
NCT06290934 is a Phase 2 study of Ulcerative Colitis that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 228 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290934, a Phase 2 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Primary Outcome
Clinical response is defined as a decrease from baseline in the modified Mayo Clinic Score (mMCS) of ≥ 2 points and at least a 30% reduction from baseline, and a decrease in rectal bleeding subscore of ≥ 1 from baseline or an absolute rectal bleeding subscore of 0 or 1. The mMCS is a scoring system for assessment of Ulcerative Colitis (UC) activity and is composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulcera
Conditions Studied
Interventions
- DRUG GS-1427
- DRUG Placebo-to-match GS-1427
Study Locations (20)
California
- Om Research LLC - Camarillo
- VVCRD Research - Garden Grove
- 310 Clinical Research - Inglewood
- US San Diego Health System - La Jolla
- Om Research LLC - Lancaster
- UCSF Benioff Children's Hospital Oakland - Oakland
- University Of California, Davis - Sacramento
- SDG Clinical Research, LLC - San Diego
- Acclaim Clinical Research - San Diego
Florida
- Gastro Florida - Clearwater
- Best Quality Research, Inc - Hialeah
- United Research Institute LLC - Hialeah
- University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center(Drug shipment)-Research Pharmacy - Miami
- Medical Professional Clinical Research Center, Inc. - Miami
- Blessed Health Care & Research, Inc - Miami
- Alliance Clinical Research of Tampa, LLC - New Port Richey
- Digestive and Liver Center of Florida, LLC - Orlando
Colorado
- Peak Gastroenterology Associates - Colorado Springs
- Peak Gastroenterology Associates - Colorado Springs
Arizona
- Onyx Clinical Research (Clinic Location) - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What the registry record for NCT06290934 still lists
NCT06290934 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which GS-1427 is the first listed.
NCT06290934 names 20 study sites across 4 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06290934 about?
NCT06290934 is a clinical study titled "Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis". The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to as...
What is the current status of trial NCT06290934?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2024-03-27. Estimated completion is 2028-04.
What conditions does trial NCT06290934 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06290934?
The interventions under investigation include: GS-1427 (DRUG), Placebo-to-match GS-1427 (DRUG).
Who is sponsoring clinical trial NCT06290934?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290934 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06290934's enrollment target sits among peer trials
228 40th of 122 higher than 83 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI